関連レポート

液体生検(リキッドバイオプシー）市場：2031年予測

出版元：MarketsandMarkets  出版元について

発行年：2024年5月

定価：Single User License $4950 Multi User License $6650 Corporate User License $8150

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 328ページになります。

商品コード：MAM3625

当レポートの更新版の制作依頼、部分購入やご希望情報の追加等、ご相談可能です。

レポート紹介

液体生検(リキッドバイオプシー）の世界市場規模は2024年で64億ドル、2029年に113億ドル、市場の平均年成長率は11.9%にて増加すると見込まれています。

レポートは液体生検(リキッドバイオプシー）の世界市場について2029年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測（製品サービス別市場、循環バイオマーカー別市場、等）を中心に構成されています。また競合状況、主要企業情報（13社）、エコシステム分析、ファイブフォース分析なども加味し、液体生検(リキッドバイオプシー）市場の動向および今後成長性を詳細にレポートしています。

【レポート構成概要】
◆液体生検(リキッドバイオプシー）市場の世界市場予測2022-2029年
・市場規模(US$)

◆製品サービス別、市場-2029年
・アッセイキット
・器具
・サービス
※(市場規模US$)　

◆循環バイオマーカー別、市場-2029年
・循環腫瘍細胞
・循環腫瘍DNA
・セルフリーDNA
・細胞外小胞
・その他循環バイオマーカー
※(市場規模US$)　

◆技術別、市場-2029年
・次世代シーケンス解析（NGS）を用いたマルチ遺伝子並列解析
・ポリメラーゼ連鎖反応（PCR）を用いたシングル遺伝子解析
※(市場規模US$)　

◆用途別、市場-2029年
がん領域
・肺がん
・乳がん
・大腸がん
・前立腺がん
・悪性黒色腫
・その他がん

非がん領域
・非侵襲的出生前検査
・臓器移植
・感染症検査
※(市場規模US$)　

◆臨床用途別、市場-2029年
・治療法選択
・治療モニタリング
・早期がん検診
・再発モニタリング
※(市場規模US$)　

◆サンプルタイプ別、市場-2029年
・血液サンプル
・その他サンプルタイプ
※(市場規模US$)　

◆エンドユーザー別、市場-2029年
・リファレンスラボラトリー
・病院、医師研究所
・学術研究センター
・その他エンドユーザー
※(市場規模US$)　

◆主要国地域別市場-2029年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国
※地域別に、国別に、全セグメント別の細分化データ掲載、詳細は目次参照

◆市場分析
・市場ダイナミクス
・平均価格分析
・特許分析
・バリューチェーン分析
・サプライチェーン分析
・貿易分析
・エコシステム分析
・ファイブフォース分析
・主要なステークホルダーと購買基準
・規制状況
・技術分析
・ケーススタディ分析
・競合状況
・市場シェア分析

◆液体生検(リキッドバイオプシー）市場の主要企業プロフィール動向
・NATERA, INC
・QIAGEN
・MYRIAD GENETICS, INC
・ILLUMINA, INC
・F HOFFMANN-LA ROCHE LTD
・THERMO FISHER SCIENTIFIC INC
・GUARDANT HEALTH
・BIO-RAD LABORATORIES, INC
・EXACT SCIENCES CORPORATION
・シスメックス株式会社
・BIOCEPT, INC
・MDXHEALTH
・PERSONALIS, INC

その他企業
・NEOGENOMICS LABORATORIES
・EPIGENOMICS AG
・ANGLE PLC
・MENARINI-SILICON BIOSYSTEMS
・LUNGLIFE AI, INC
・VORTEX BIOSCIENCES
・BIO-TECHNE
・MESA LABS, INC
・LABORATORY CORPORATION OF AMERICA HOLDINGS
・MEDGENOME
・STRAND
・FREENOME HOLDINGS, INC
・LUCENCE HEALTH INC

（全328頁）

Table of Contents (英文詳細目次）

1 INTRODUCTION 48

1.1 STUDY OBJECTIVES 48
1.2 MARKET DEFINITION 48
1.2.1 INCLUSIONS & EXCLUSIONS 49
1.3 STUDY SCOPE 49
1.3.1 MARKETS COVERED 49
1.3.2 REGIONS COVERED 50
1.3.3 YEARS CONSIDERED 50
1.3.4 CURRENCY CONSIDERED 50
1.4 STAKEHOLDERS 51
1.5 SUMMARY OF CHANGES 51
1.5.1 RECESSION IMPACT 52

2 RESEARCH METHODOLOGY 53

2.1 RESEARCH DATA 53
2.2 RESEARCH APPROACH 53
・ FIGURE 1 LIQUID BIOPSY MARKET: RESEARCH DESIGN METHODOLOGY 53
2.2.1 SECONDARY DATA 54
2.2.1.1 KEY DATA FROM SECONDARY SOURCES 54
2.2.2 PRIMARY DATA 55
2.2.2.1 PRIMARY SOURCES 56
2.2.2.2 KEY DATA FROM PRIMARY SOURCES 56
2.2.2.3 KEY INDUSTRY INSIGHTS 57
2.2.2.4 BREAKDOWN OF PRIMARY INTERVIEWS 57
・ FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS 58
・ FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 58
2.3 MARKET SIZE ESTIMATION 58
2.3.1 BOTTOM-UP APPROACH 59
2.3.1.1 APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH 59
・ FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 59
2.3.1.2 APPROACH 2: PRESENTATIONS OF COMPANIES AND PRIMARY INTERVIEWS 59
2.3.1.3 GROWTH FORECAST 60
2.3.1.4 CAGR PROJECTIONS 60
・ FIGURE 5 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS 60
2.3.2 TOP-DOWN APPROACH 60
・ FIGURE 6 LIQUID BIOPSY MARKET: TOP-DOWN APPROACH 61
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 62
・ FIGURE 7 DATA TRIANGULATION METHODOLOGY 62
2.5 STUDY ASSUMPTIONS 63
2.6 GROWTH RATE ASSUMPTIONS 63
2.7 RESEARCH LIMITATIONS 63
2.8 RISK ASSESSMENT 64
2.9 RECESSION IMPACT ANALYSIS 64

3 EXECUTIVE SUMMARY 66

・ FIGURE 8 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION) 66
・ FIGURE 9 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2024 VS. 2029 (USD MILLION) 67
・ FIGURE 10 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION) 67
・ FIGURE 11 LIQUID BIOPSY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 68
・ FIGURE 12 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2024 VS. 2029 (USD MILLION) 68
・ FIGURE 13 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2024 VS. 2029 (USD MILLION) 69
・ FIGURE 14 LIQUID BIOPSY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 70
・ FIGURE 15 LIQUID BIOPSY MARKET, BY REGION, 2024 VS. 2029 (USD MILLION) 70

4 PREMIUM INSIGHTS 72

4.1 LIQUID BIOPSY MARKET OVERVIEW 72
・ FIGURE 16 INCREASING DEMAND FOR MINIMALLY INVASIVE DIAGNOSTIC TECHNIQUES TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD 72
4.2 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION) 73
・ FIGURE 17 ASSAY KITS SEGMENT TO DOMINATE MARKET THROUGHOUT FORECAST PERIOD 73
4.3 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2024 VS. 2029 (USD MILLION) 73
・ FIGURE 18 CIRCULATING TUMOR CELLS SEGMENT TO HOLD LARGEST MARKET SHARE TILL 2029 73
4.4 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION) 74
・ FIGURE 19 MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT TO ACCOUNT FOR LARGEST SHARE OF TECHNOLOGY MARKET 74
4.5 LIQUID BIOPSY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 74
・ FIGURE 20 CANCER APPLICATIONS SEGMENT TO RETAIN MARKET DOMINANCE TILL 2029 74
4.6 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2024 VS. 2029 (USD MILLION) 75
・ FIGURE 21 THERAPY SELECTION AND TREATMENT MONITORING TO HOLD LARGEST MARKET SHARES THROUGHOUT FORECAST PERIOD 75
4.7 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2024 VS. 2029 (USD MILLION) 75
・ FIGURE 22 BLOOD SAMPLES TO DOMINATE MARKET TILL 2029 75
4.8 LIQUID BIOPSY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 76
・ FIGURE 23 REFERENCE LABORATORIES TO ACCOUNT FOR LARGEST SHARE 76
4.9 LIQUID BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 76
・ FIGURE 24 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 76

5 MARKET OVERVIEW 77

5.1 INTRODUCTION 77
5.2 MARKET DYNAMICS 77
・ FIGURE 25 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 77
5.2.1 DRIVERS 78
5.2.1.1 RISING INCIDENCE AND PREVALENCE OF CANCER 78
・ TABLE 1 INCIDENCE OF CANCER CASES WORLDWIDE, BY TYPE (2022) 78
・ TABLE 2 PROJECTED INCREASE IN CANCER PATIENTS, BY REGION (2022 VS 2035 VS 2045) 79
5.2.1.2 CANCER AWARENESS INITIATIVES UNDERTAKEN BY GLOBAL HEALTH ORGANIZATIONS 79
5.2.1.3 BENEFITS OF LIQUID BIOPSY OVER TRADITIONAL BIOPSY PROCEDURES 80
5.2.2 RESTRAINTS 81
5.2.2.1 LOWER SENSITIVITY OF CERTAIN LIQUID BIOPSY PROCEDURES 81
5.2.3 OPPORTUNITIES 81
5.2.3.1 GROWING SIGNIFICANCE OF COMPANION DIAGNOSTICS 81
5.2.3.2 GROWTH OPPORTUNITIES IN EMERGING COUNTRIES 82
5.2.4 CHALLENGES 82
5.2.4.1 UNCLEAR REIMBURSEMENT SCENARIO 82
5.3 PRICING ANALYSIS 83
・ TABLE 3 INDICATIVE PRICING OF KEY PLAYERS, BY PRODUCT 83
5.4 PATENT ANALYSIS 85
・ FIGURE 26 PATENT ANALYSIS FOR LIQUID BIOPSY (JANUARY 2014–DECEMBER 2023) 85
5.4.1 LIST OF MAJOR PATENTS 85
5.5 VALUE CHAIN ANALYSIS 86
・ FIGURE 27 VALUE CHAIN ANALYSIS OF LIQUID BIOPSY MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 87
5.6 SUPPLY CHAIN ANALYSIS 87
・ FIGURE 28 LIQUID BIOPSY MARKET: SUPPLY CHAIN ANALYSIS 88
5.7 TRADE ANALYSIS 88
5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 88
・ TABLE 6 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 88
・ TABLE 7 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 89
5.8 ECOSYSTEM ANALYSIS 89
・ FIGURE 29 LIQUID BIOPSY MARKET: ECOSYSTEM ANALYSIS 89
5.8.1 LIQUID BIOPSY MARKET PLAYERS: ROLE IN ECOSYSTEM 89
5.9 PORTER’S FIVE FORCES ANALYSIS 90
5.9.1 THREAT OF NEW ENTRANTS 90
5.9.2 THREAT OF SUBSTITUTES 90
5.9.3 BARGAINING POWER OF BUYERS 90
5.9.4 BARGAINING POWER OF SUPPLIERS 90
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 91
5.10 KEY STAKEHOLDERS & BUYING CRITERIA 91
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 91
・ FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS 91
・ TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS (%) 91
5.10.2 BUYING CRITERIA 92
・ FIGURE 31 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS 92
・ TABLE 10 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS 92
5.11 REGULATORY LANDSCAPE 92
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
・ TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
5.11.2 NORTH AMERICA 94
5.11.2.1 US 94
5.11.2.2 CANADA 94
5.11.3 EUROPE 94
・ TABLE 16 EUROPE: CLASSIFICATION OF DEVICES 95
5.11.4 ASIA PACIFIC 95
5.11.4.1 CHINA 95
5.11.4.2 JAPAN 95
・ TABLE 17 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 96
5.11.4.3 INDIA 96
5.11.5 LATIN AMERICA 96
5.11.5.1 BRAZIL 96
5.11.5.2 MEXICO 97
5.11.6 MIDDLE EAST 97
5.11.6.1 AFRICA 97
5.12 TECHNOLOGY ANALYSIS 97
5.12.1 KEY TECHNOLOGIES 97
5.12.1.1 DIGITAL DROPLET PCR 97
5.12.1.2 TAGGED-AMPLICON DEEP SEQUENCING 98
5.12.2 COMPLEMENTARY TECHNOLOGIES 98
5.12.2.1 ELECTROCHEMICAL BIOSENSING TECHNOLOGY 98
5.12.3 ADJACENT TECHNOLOGIES 98
5.12.3.1 MICROFLUIDICS-BASED DEVICES 98
5.13 KEY CONFERENCES & EVENTS IN 2024–2025 99
・ TABLE 18 LIQUID BIOPSY MARKET: DETAILED LIST OF CONFERENCES & EVENTS 99
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 100
・ FIGURE 32 REVENUE SHIFT IN LIQUID BIOPSY MARKET 100
5.15 INVESTMENT & FUNDING SCENARIO 100
・ FIGURE 33 LIQUID BIOPSY MARKET: INVESTMENT & FUNDING SCENARIO 100
5.16 CASE STUDY ANALYSIS 101
5.16.1 CASE STUDY 1: ANALYTICAL VALIDATION OF TARGET SELECTOR CTDNA PLATFORM 101
5.16.2 CASE STUDY 2: DETERMINING OPTIMAL MUTATION DETECTION MEDIUM 101

6 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE 102

6.1 INTRODUCTION 103
・ TABLE 19 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 103
6.1.1 PRIMARY NOTES 103
6.1.1.1 KEY INDUSTRY INSIGHTS 103
6.2 ASSAY KITS 104
6.2.1 RECURRENT REQUIREMENTS AND PURCHASES OF ASSAY KITS TO DRIVE GROWTH 104
・ TABLE 20 KEY PRODUCTS IN ASSAY KITS MARKET 105
・ TABLE 21 LIQUID BIOPSY ASSAY KITS MARKET, BY REGION, 2022–2029 (USD MILLION) 105
・ TABLE 22 NORTH AMERICA: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 106
・ TABLE 23 EUROPE: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 106
・ TABLE 24 ASIA PACIFIC: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 106
・ TABLE 25 LATIN AMERICA: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 107
6.3 INSTRUMENTS 107
6.3.1 INCREASING NEED FOR FASTER & MORE ACCURATE TEST RESULTS TO ENSURE MARKET GROWTH 107
・ TABLE 26 KEY PRODUCTS IN INSTRUMENTS MARKET 108
・ TABLE 27 LIQUID BIOPSY INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 108
・ TABLE 28 NORTH AMERICA: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 109
・ TABLE 29 EUROPE: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 109
・ TABLE 30 ASIA PACIFIC: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 109
・ TABLE 31 LATIN AMERICA: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 110
6.4 SERVICES 110
6.4.1 INCREASING NUMBER OF LIQUID BIOPSY-BASED SERVICE DEVELOPMENTS TO SUPPORT MARKET GROWTH 110
・ TABLE 32 LIQUID BIOPSY SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 111
・ TABLE 33 NORTH AMERICA: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 111
・ TABLE 34 EUROPE: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 111
・ TABLE 35 ASIA PACIFIC: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 112
・ TABLE 36 LATIN AMERICA: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 112

7 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER 113

7.1 INTRODUCTION 114
・ TABLE 37 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 114
7.2 CIRCULATING TUMOR CELLS 114
7.2.1 EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF TUMOR BURDEN TO DRIVE DEMAND 114
・ TABLE 38 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2022–2029 (USD MILLION) 115
・ TABLE 39 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 115
・ TABLE 40 EUROPE: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 116
・ TABLE 41 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 116
・ TABLE 42 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 116
7.3 CIRCULATING TUMOR DNA 117
7.3.1 HIGH SENSITIVITY AND SPECIFICITY TO FAVOR ADOPTION 117
・ TABLE 43 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2022–2029 (USD MILLION) 118
・ TABLE 44 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2022–2029 (USD MILLION) 118
・ TABLE 45 EUROPE: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2022–2029 (USD MILLION) 118
・ TABLE 46 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2022–2029 (USD MILLION) 119
・ TABLE 47 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2022–2029 (USD MILLION) 119
7.4 CELL-FREE DNA 119
7.4.1 GROWING APPLICATION OF CFDNA IN PRENATAL SCREENING TO DRIVE GROWTH 119
・ TABLE 48 LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY REGION, 2022–2029 (USD MILLION) 120
・ TABLE 49 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2022–2029 (USD MILLION) 120
・ TABLE 50 EUROPE: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2022–2029 (USD MILLION) 120
・ TABLE 51 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2022–2029 (USD MILLION) 121
・ TABLE 52 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2022–2029 (USD MILLION) 121
7.5 EXTRACELLULAR VESICLES 121
7.5.1 HIGH STABILITY IN BLOOD CIRCULATION TO ENSURE CONSISTENT GROWTH 121
・ TABLE 53 LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2022–2029 (USD MILLION) 122
・ TABLE 54 NORTH AMERICA: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2022–2029 (USD MILLION) 122
・ TABLE 55 EUROPE: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2022–2029 (USD MILLION) 123
・ TABLE 56 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2022–2029 (USD MILLION) 123
・ TABLE 57 LATIN AMERICA: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2022–2029 (USD MILLION) 123
7.6 OTHER CIRCULATING BIOMARKERS 124
・ TABLE 58 LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2022–2029 (USD MILLION) 124
・ TABLE 59 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2022–2029 (USD MILLION) 124
・ TABLE 60 EUROPE: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2022–2029 (USD MILLION) 125
・ TABLE 61 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2022–2029 (USD MILLION) 125
・ TABLE 62 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2022–2029 (USD MILLION) 125

8 LIQUID BIOPSY MARKET, BY TECHNOLOGY 126

8.1 INTRODUCTION 127
・ TABLE 63 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 127
・ TABLE 64 NUMBER OF LIQUID BIOPSY SAMPLES TESTED GLOBALLY, BY TECHNOLOGY, 2022–2029 (MILLIONS) 127
8.1.1 KEY INDUSTRY INSIGHTS 128
8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS 128
8.2.1 HIGH SENSITIVITY COUPLED WITH HIGHER THROUGHPUT EFFICIENCY TO DRIVE GROWTH 128
・ TABLE 65 LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2022–2029 (USD MILLION) 129
・ TABLE 66 NORTH AMERICA: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2022–2029 (USD MILLION) 129
・ TABLE 67 EUROPE: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2022–2029 (USD MILLION) 129
・ TABLE 68 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2022–2029 (USD MILLION) 130
・ TABLE 69 LATIN AMERICA: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2022–2029 (USD MILLION) 130
8.3 SINGLE-GENE ANALYSIS USING PCR 130
8.3.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION 130
・ TABLE 70 LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR, BY REGION, 2022–2029 (USD MILLION) 131
・ TABLE 71 NORTH AMERICA: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR, BY COUNTRY, 2022–2029 (USD MILLION) 131
・ TABLE 72 EUROPE: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR, BY COUNTRY, 2022–2029 (USD MILLION) 131
・ TABLE 73 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR, BY COUNTRY, 2022–2029 (USD MILLION) 132
・ TABLE 74 LATIN AMERICA: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR, BY COUNTRY, 2022–2029 (USD MILLION) 132

9 LIQUID BIOPSY MARKET, BY APPLICATION 133

9.1 INTRODUCTION 134
・ TABLE 75 LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 134
9.2 CANCER APPLICATIONS 134
・ TABLE 76 GLOBAL CANCER INCIDENCE, 2022 VS. 2045, BY REGION 135
・ TABLE 77 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 136
・ TABLE 78 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 136
・ TABLE 79 EUROPE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 136
・ TABLE 80 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 137
・ TABLE 81 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 137
・ TABLE 82 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 137
9.2.1 LUNG CANCER 138
9.2.1.1 GROWING PREVALENCE OF LUNG CANCER TO PROPEL MARKET GROWTH 138
・ TABLE 83 GLOBAL LUNG CANCER INCIDENCE, 2022 VS. 2045 139
・ TABLE 84 LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION, 2022–2029 (USD MILLION) 139
・ TABLE 85 NORTH AMERICA: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 139
・ TABLE 86 EUROPE: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 140
・ TABLE 87 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 140
・ TABLE 88 LATIN AMERICA: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 140
9.2.2 BREAST CANCER 141
9.2.2.1 INCREASING FUNDING FOR BREAST CANCER RESEARCH TO SPUR GROWTH 141
・ TABLE 89 GLOBAL BREAST CANCER INCIDENCE, 2022 VS. 2045 142
・ TABLE 90 LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION, 2022–2029 (USD MILLION) 142
・ TABLE 91 NORTH AMERICA: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 142
・ TABLE 92 EUROPE: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 143
・ TABLE 93 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 143
・ TABLE 94 LATIN AMERICA: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 143
9.2.3 COLORECTAL CANCER 144
9.2.3.1 RISING PREVALENCE OF COLORECTAL CANCER TO PROPEL MARKET 144
・ TABLE 95 GLOBAL COLORECTAL CANCER INCIDENCE, 2022 VS. 2045 144
・ TABLE 96 LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION, 2022–2029 (USD MILLION) 145
・ TABLE 97 NORTH AMERICA: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 145
・ TABLE 98 EUROPE: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 145
・ TABLE 99 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 146
・ TABLE 100 LATIN AMERICA: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 146
9.2.4 PROSTATE CANCER 146
9.2.4.1 RISING PATIENT POPULATION TO SUPPORT MARKET GROWTH 146
・ TABLE 101 GLOBAL PROSTATE CANCER INCIDENCE, 2022 VS. 2045 147
・ TABLE 102 LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2022–2029 (USD MILLION) 147
・ TABLE 103 NORTH AMERICA: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 148
・ TABLE 104 EUROPE: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 148
・ TABLE 105 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 148
・ TABLE 106 LATIN AMERICA: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 149
9.2.5 MELANOMA 149
9.2.5.1 GROWING NEED FOR EARLY DIAGNOSIS OF GENETICALLY MUTATED TUMORS TO DRIVE MARKET 149
・ TABLE 107 GLOBAL MELANOMA INCIDENCE, 2022 VS. 2045 150
・ TABLE 108 LIQUID BIOPSY MARKET FOR MELANOMA, BY REGION, 2022–2029 (USD MILLION) 150
・ TABLE 109 NORTH AMERICA: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2022–2029 (USD MILLION) 150
・ TABLE 110 EUROPE: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2022–2029 (USD MILLION) 151
・ TABLE 111 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2022–2029 (USD MILLION) 151
・ TABLE 112 LATIN AMERICA: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2022–2029 (USD MILLION) 151
9.2.6 OTHER CANCERS 152
・ TABLE 113 GLOBAL INCIDENCE OF OTHER CANCERS, 2022 152
・ TABLE 114 LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY REGION, 2022–2029 (USD MILLION) 152
・ TABLE 115 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION) 153
・ TABLE 116 EUROPE: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION) 153
・ TABLE 117 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION) 153
・ TABLE 118 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION) 154
9.3 NON-CANCER APPLICATIONS 154
・ TABLE 119 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 154
・ TABLE 120 NORTH AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 155
・ TABLE 121 EUROPE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 155
・ TABLE 122 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 155
・ TABLE 123 LATIN AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 156
・ TABLE 124 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 156
9.3.1 NON-INVASIVE PRENATAL TESTING 156
9.3.1.1 GROWING DEMAND FOR NIPT IN HIGH-RISK PREGNANCIES TO DRIVE MARKET 156
・ TABLE 125 LIQUID BIOPSY MARKET FOR NIPT, BY REGION, 2022–2029 (USD MILLION) 157
・ TABLE 126 NORTH AMERICA: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2022–2029 (USD MILLION) 157
・ TABLE 127 EUROPE: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2022–2029 (USD MILLION) 157
・ TABLE 128 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2022–2029 (USD MILLION) 158
・ TABLE 129 LATIN AMERICA: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2022–2029 (USD MILLION) 158
9.3.2 ORGAN TRANSPLANTATION 158
9.3.2.1 NEED FOR EARLY DETECTION OF REJECTION TO IMPROVE SURVIVAL CHANCES TO DRIVE GROWTH 158
・ TABLE 130 LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY REGION, 2022–2029 (USD MILLION) 159
・ TABLE 131 NORTH AMERICA: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2022–2029 (USD MILLION) 159
・ TABLE 132 EUROPE: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2022–2029 (USD MILLION) 159
・ TABLE 133 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2022–2029 (USD MILLION) 160
・ TABLE 134 LATIN AMERICA: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2022–2029 (USD MILLION) 160
9.3.3 INFECTIOUS DISEASE TESTING 160
9.3.3.1 POTENTIAL ACCURACY AND EFFICACY TO SUPPORT DEVELOPMENT OF NOVEL TESTS 160
・ TABLE 135 LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2022–2029 (USD MILLION) 161
・ TABLE 136 NORTH AMERICA: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2022–2029 (USD MILLION) 161
・ TABLE 137 EUROPE: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2022–2029 (USD MILLION) 162
・ TABLE 138 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2022–2029 (USD MILLION) 162
・ TABLE 139 LATIN AMERICA: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2022–2029 (USD MILLION) 162

10 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION 163

10.1 INTRODUCTION 164
・ TABLE 140 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 164
10.2 THERAPY SELECTION 164
10.2.1 THERAPY SELECTION TO HOLD LARGEST SHARE 164
・ TABLE 141 LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY REGION, 2022–2029 (USD MILLION) 165
・ TABLE 142 NORTH AMERICA: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2022–2029 (USD MILLION) 165
・ TABLE 143 EUROPE: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2022–2029 (USD MILLION) 166
・ TABLE 144 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2022–2029 (USD MILLION) 166
・ TABLE 145 LATIN AMERICA: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2022–2029 (USD MILLION) 166
10.3 TREATMENT MONITORING 167
10.3.1 EARLY DETECTION OF ALTERATIONS ASSOCIATED WITH DRUG RESISTANCE TO DRIVE ADOPTION 167
・ TABLE 146 LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY REGION, 2022–2029 (USD MILLION) 167
・ TABLE 147 NORTH AMERICA: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2022–2029 (USD MILLION) 168
・ TABLE 148 EUROPE: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2022–2029 (USD MILLION) 168
・ TABLE 149 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2022–2029 (USD MILLION) 168
・ TABLE 150 LATIN AMERICA: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2022–2029 (USD MILLION) 169
10.4 EARLY CANCER SCREENING 169
10.4.1 POTENTIAL FOR EARLY CANCER DETECTION TO DRIVE MARKET 169
・ TABLE 151 LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY REGION, 2022–2029 (USD MILLION) 170
・ TABLE 152 NORTH AMERICA: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2022–2029 (USD MILLION) 170
・ TABLE 153 EUROPE: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2022–2029 (USD MILLION) 170
・ TABLE 154 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2022–2029 (USD MILLION) 171
・ TABLE 155 LATIN AMERICA: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2022–2029 (USD MILLION) 171
10.5 RECURRENCE MONITORING 171
10.5.1 NEED FOR POST-TREATMENT SURVEILLANCE TO DRIVE DEMAND 171
・ TABLE 156 LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY REGION, 2022–2029 (USD MILLION) 172
・ TABLE 157 NORTH AMERICA: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2022–2029 (USD MILLION) 172
・ TABLE 158 EUROPE: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2022–2029 (USD MILLION) 173
・ TABLE 159 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2022–2029 (USD MILLION) 173
・ TABLE 160 LATIN AMERICA: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2022–2029 (USD MILLION) 173

11 LIQUID BIOPSY MARKET, BY SAMPLE TYPE 174

11.1 INTRODUCTION 175
・ TABLE 161 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 175
・ TABLE 162 LIQUID BIOPSY SAMPLES AND APPLICATIONS 175
11.1.1 KEY INDUSTRY INSIGHTS 176
11.2 BLOOD SAMPLES 176
11.2.1 SIMPLICITY, NON-INVASIVENESS TO DRIVE UPTAKE 176
・ TABLE 163 LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY REGION, 2022–2029 (USD MILLION) 177
・ TABLE 164 NORTH AMERICA: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 177
・ TABLE 165 EUROPE: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 178
・ TABLE 166 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 178
・ TABLE 167 LATIN AMERICA: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 178
11.3 OTHER SAMPLE TYPES 179
・ TABLE 168 LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2022–2029 (USD MILLION) 179
・ TABLE 169 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION) 180
・ TABLE 170 EUROPE: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION) 180
・ TABLE 171 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION) 180
・ TABLE 172 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION) 181

12 LIQUID BIOPSY MARKET, BY END USER 182

12.1 INTRODUCTION 183
・ TABLE 173 LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 183
12.2 REFERENCE LABORATORIES 183
12.2.1 INCREASING OUTSOURCING OF LIQUID BIOPSY TESTS TO DRIVE MARKET 183
・ TABLE 174 LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY REGION, 2022–2029 (USD MILLION) 184
・ TABLE 175 NORTH AMERICA: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 184
・ TABLE 176 EUROPE: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 185
・ TABLE 177 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 185
・ TABLE 178 LATIN AMERICA: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 185
12.3 HOSPITALS & PHYSICIAN LABORATORIES 186
12.3.1 GROWING NUMBER OF HOSPITALS WORLDWIDE TO BOOST GROWTH 186
・ TABLE 179 LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIAN LABORATORIES, BY REGION, 2022–2029 (USD MILLION) 186
・ TABLE 180 NORTH AMERICA: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIAN LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 187
・ TABLE 181 EUROPE: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIAN LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 187
・ TABLE 182 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIAN LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 187
・ TABLE 183 LATIN AMERICA: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIAN LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 188
12.4 ACADEMIC & RESEARCH CENTERS 188
12.4.1 GROWING FOCUS ON R&D INTO INNOVATIVE LIQUID BIOPSY TESTS TO FUEL GROWTH 188
・ TABLE 184 LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2022–2029 (USD MILLION) 189
・ TABLE 185 NORTH AMERICA: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 189
・ TABLE 186 EUROPE: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 189
・ TABLE 187 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 190
・ TABLE 188 LATIN AMERICA: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 190
12.5 OTHER END USERS 190
・ TABLE 189 LIQUID BIOPSY MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION) 191
・ TABLE 190 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 191
・ TABLE 191 EUROPE: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 191
・ TABLE 192 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 192
・ TABLE 193 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 192

13 LIQUID BIOPSY MARKET, BY REGION 193

13.1 INTRODUCTION 194
・ TABLE 194 LIQUID BIOPSY MARKET, BY REGION, 2022–2029 (USD MILLION) 194
13.2 NORTH AMERICA 194
・ TABLE 195 NORTH AMERICA: NUMBER OF NEW CANCER CASES, BY CANCER TYPE, 2022 195
13.2.1 NORTH AMERICA: RECESSION IMPACT 195
・ FIGURE 34 NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT 196
・ TABLE 196 NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 196
・ TABLE 197 NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 197
・ TABLE 198 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 197
・ TABLE 199 NORTH AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 197
・ TABLE 200 NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 198
・ TABLE 201 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 198
・ TABLE 202 NORTH AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 198
・ TABLE 203 NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 199
13.2.2 US 199
13.2.2.1 INCREASING PREVALENCE OF CANCER TO DRIVE GROWTH 199
・ TABLE 204 US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 200
・ TABLE 205 US: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 200
・ TABLE 206 US: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 200
・ TABLE 207 US: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 201
・ TABLE 208 US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 201
・ TABLE 209 US: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 201
・ TABLE 210 US: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 202
13.2.3 CANADA 202
13.2.3.1 AVAILABILITY OF VARIOUS CANCER SCREENING PROGRAMS TO DRIVE GROWTH 202
・ TABLE 211 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 203
・ TABLE 212 CANADA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 203
・ TABLE 213 CANADA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 204
・ TABLE 214 CANADA: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 204
・ TABLE 215 CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 204
・ TABLE 216 CANADA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 205
・ TABLE 217 CANADA: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 205
13.3 EUROPE 205
13.3.1 EUROPE: RECESSION IMPACT 206
・ TABLE 218 EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 206
・ TABLE 219 EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 207
・ TABLE 220 EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 207
・ TABLE 221 EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 207
・ TABLE 222 EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 208
・ TABLE 223 EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 208
・ TABLE 224 EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 208
・ TABLE 225 EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 209
13.3.2 GERMANY 209
13.3.2.1 FAVORABLE GOVERNMENT HEALTH POLICIES TO SUPPORT MARKET GROWTH 209
・ TABLE 226 GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 210
・ TABLE 227 GERMANY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 210
・ TABLE 228 GERMANY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 210
・ TABLE 229 GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 211
・ TABLE 230 GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 211
・ TABLE 231 GERMANY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 211
・ TABLE 232 GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 212
13.3.3 UK 212
13.3.3.1 RISING GOVERNMENT HEALTHCARE EXPENDITURE TO PROPEL MARKET GROWTH 212
・ TABLE 233 UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 213
・ TABLE 234 UK: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 213
・ TABLE 235 UK: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 213
・ TABLE 236 UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 214
・ TABLE 237 UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 214
・ TABLE 238 UK: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 214
・ TABLE 239 UK: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 215
13.3.4 FRANCE 215
13.3.4.1 RISING R&D EXPENDITURE TO DRIVE MARKET GROWTH 215
・ TABLE 240 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 215
・ TABLE 241 FRANCE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 216
・ TABLE 242 FRANCE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 216
・ TABLE 243 FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 216
・ TABLE 244 FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 217
・ TABLE 245 FRANCE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 217
・ TABLE 246 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 217
13.3.5 ITALY 218
13.3.5.1 GROWING RESEARCH INTO NOVEL CIRCULATING CANCER BIOMARKERS TO DRIVE MARKET GROWTH 218
・ TABLE 247 ITALY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 218
・ TABLE 248 ITALY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 219
・ TABLE 249 ITALY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 219
・ TABLE 250 ITALY: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 219
・ TABLE 251 ITALY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 220
・ TABLE 252 ITALY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 220
・ TABLE 253 ITALY: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 220
13.3.6 SPAIN 221
13.3.6.1 FOCUS ON PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH 221
・ TABLE 254 SPAIN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 221
・ TABLE 255 SPAIN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 222
・ TABLE 256 SPAIN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 222
・ TABLE 257 SPAIN: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 222
・ TABLE 258 SPAIN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 223
・ TABLE 259 SPAIN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 223
・ TABLE 260 SPAIN: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 223
13.3.7 REST OF EUROPE 224
・ TABLE 261 REST OF EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 224
・ TABLE 262 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 225
・ TABLE 263 REST OF EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 225
・ TABLE 264 REST OF EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 225
・ TABLE 265 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 226
・ TABLE 266 REST OF EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 226
・ TABLE 267 REST OF EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 226
13.4 ASIA PACIFIC 227
13.4.1 ASIA PACIFIC: RECESSION IMPACT 227
・ FIGURE 35 ASIA PACIFIC: LIQUID BIOPSY MARKET SNAPSHOT 228
・ TABLE 268 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 228
・ TABLE 269 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 229
・ TABLE 270 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 229
・ TABLE 271 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 229
・ TABLE 272 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 230
・ TABLE 273 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 230
・ TABLE 274 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 230
・ TABLE 275 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 231
13.4.2 CHINA 231
13.4.2.1 GROWING PUBLIC ACCESS TO ADVANCED HEALTHCARE FACILITIES TO DRIVE MARKET 231
・ TABLE 276 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 232
・ TABLE 277 CHINA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 232
・ TABLE 278 CHINA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 232
・ TABLE 279 CHINA: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 233
・ TABLE 280 CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 233
・ TABLE 281 CHINA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 233
・ TABLE 282 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 234
13.4.3 JAPAN 234
13.4.3.1 UNIVERSAL HEALTHCARE REIMBURSEMENT POLICY TO FUEL GROWTH 234
・ TABLE 283 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 235
・ TABLE 284 JAPAN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 235
・ TABLE 285 JAPAN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 235
・ TABLE 286 JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 236
・ TABLE 287 JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 236
・ TABLE 288 JAPAN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 236
・ TABLE 289 JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 237
13.4.4 INDIA 237
13.4.4.1 INCREASING INVESTMENTS IN HEALTHCARE SYSTEMS TO DRIVE ADOPTION OF LIQUID BIOPSY PRODUCTS 237
・ TABLE 290 INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 238
・ TABLE 291 INDIA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 238
・ TABLE 292 INDIA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 239
・ TABLE 293 INDIA: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 239
・ TABLE 294 INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 239
・ TABLE 295 INDIA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 240
・ TABLE 296 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 240
13.4.5 REST OF ASIA PACIFIC 240
・ TABLE 297 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 241
・ TABLE 298 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 241
・ TABLE 299 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 242
・ TABLE 300 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 242
・ TABLE 301 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 242
・ TABLE 302 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 243
・ TABLE 303 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 243
13.5 LATIN AMERICA 243
13.5.1 INCREASING PRIVATE & PUBLIC INVESTMENTS TO DRIVE MARKET 243
13.5.2 LATIN AMERICA: RECESSION IMPACT 244
・ TABLE 304 LATIN AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 244
・ TABLE 305 LATIN AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 245
・ TABLE 306 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 245
・ TABLE 307 LATIN AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 245
・ TABLE 308 LATIN AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 246
・ TABLE 309 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 246
・ TABLE 310 LATIN AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 246
・ TABLE 311 LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 247
13.5.3 BRAZIL 247
13.5.3.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND SUPPORTIVE REGULATORY ENVIRONMENT TO FUEL MARKET 247
・ TABLE 312 BRAZIL: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 247
・ TABLE 313 BRAZIL: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 248
・ TABLE 314 BRAZIL: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 248
・ TABLE 315 BRAZIL: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 248
・ TABLE 316 BRAZIL: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 249
・ TABLE 317 BRAZIL: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 249
・ TABLE 318 BRAZIL: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 249
13.5.4 MEXICO 250
13.5.4.1 IMPROVING ACCESSIBILITY AND AFFORDABILITY OF HEALTHCARE SERVICES TO SUPPORT MARKET GROWTH 250
・ TABLE 319 MEXICO: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 250
・ TABLE 320 MEXICO: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 251
・ TABLE 321 MEXICO: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 251
・ TABLE 322 MEXICO: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 251
・ TABLE 323 MEXICO: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 252
・ TABLE 324 MEXICO: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 252
・ TABLE 325 MEXICO: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 252
13.5.5 REST OF LATIN AMERICA 253
・ TABLE 326 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 253
・ TABLE 327 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 253
・ TABLE 328 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 254
・ TABLE 329 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 254
・ TABLE 330 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 254
・ TABLE 331 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 255
・ TABLE 332 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 255
13.6 MIDDLE EAST & AFRICA 255
13.6.1 INCREASED FUNDING IN RESEARCH TO DRIVE MARKET 255
13.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 256
・ TABLE 333 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 256
・ TABLE 334 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 256
・ TABLE 335 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 257
・ TABLE 336 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 257
・ TABLE 337 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 257
・ TABLE 338 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 258
・ TABLE 339 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 258
13.7 GCC COUNTRIES 258
13.7.1 RISING FOCUS ON ADVANCED HEALTH INFRASTRUCTURE TO DRIVE MARKET GROWTH 258
13.7.2 GCC COUNTRIES: RECESSION IMPACT 259
・ TABLE 340 GCC COUNTRIES: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 259
・ TABLE 341 GCC COUNTRIES: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022–2029 (USD MILLION) 260
・ TABLE 342 GCC COUNTRIES: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 260
・ TABLE 343 GCC COUNTRIES: LIQUID BIOPSY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 260
・ TABLE 344 GCC COUNTRIES: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022–2029 (USD MILLION) 261
・ TABLE 345 GCC COUNTRIES: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 261
・ TABLE 346 GCC COUNTRIES: LIQUID BIOPSY MARKET, BY END USER, 2022–2029 (USD MILLION) 261

14 COMPETITIVE LANDSCAPE 262

14.1 INTRODUCTION 262
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 262
14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN LIQUID BIOPSY MARKET 262
14.3 REVENUE ANALYSIS 264
・ FIGURE 36 TOP FIVE PLAYERS HAVE DOMINATED LIQUID BIOPSY MARKET IN LAST FIVE YEARS 264
14.4 MARKET SHARE ANALYSIS 264
14.4.1 LIQUID BIOPSY MARKET 264
・ FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023) 264
・ TABLE 347 LIQUID BIOPSY MARKET: DEGREE OF COMPETITION 265
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 266
14.5.1 STARS 266
14.5.2 EMERGING LEADERS 266
14.5.3 PERVASIVE PLAYERS 266
14.5.4 PARTICIPANTS 266
・ FIGURE 38 LIQUID BIOPSY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 267
14.5.5 COMPANY FOOTPRINT 268
・ FIGURE 39 LIQUID BIOPSY MARKET: COMPANY FOOTPRINT 268
・ TABLE 348 LIQUID BIOPSY MARKET: PRODUCT & SERVICE FOOTPRINT 268
・ TABLE 349 LIQUID BIOPSY MARKET: REGIONAL FOOTPRINT 269
・ TABLE 350 LIQUID BIOPSY MARKET: APPLICATION FOOTPRINT 269
14.6 COMPANY EVALUATION MATRIX: START-UPS/SMES 270
14.6.1 PROGRESSIVE COMPANIES 270
14.6.2 RESPONSIVE COMPANIES 270
14.6.3 DYNAMIC COMPANIES 270
14.6.4 STARTING BLOCKS 270
・ FIGURE 40 LIQUID BIOPSY MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023 271
14.6.5 COMPETITIVE BENCHMARKING 271
・ TABLE 351 LIQUID BIOPSY MARKET: DETAILED LIST OF KEY START-UPS/SMES 271
・ TABLE 352 LIQUID BIOPSY MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES 272
14.7 VALUATION AND FINANCIAL METRICS OF LIQUID BIOPSY VENDORS 272
・ FIGURE 41 EV/EBITDA OF KEY VENDORS 272
・ FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 273
14.8 BRAND/PRODUCT COMPARISON 273
・ FIGURE 43 BRAND COMPARISON: PCR-BASED LIQUID BIOPSY ASSAYS 273
14.8.1 QIAGEN 274
14.8.2 THERMO FISHER SCIENTIFIC INC. 274
14.8.3 BIO-RAD LABORATORIES, INC. 274
14.9 COMPETITIVE SCENARIO 274
14.9.1 PRODUCT LAUNCHES 274
・ TABLE 353 LIQUID BIOPSY MARKET: PRODUCT LAUNCHES, JANUARY 2021–APRIL 2024 274
14.9.2 DEALS 275
・ TABLE 354 LIQUID BIOPSY MARKET: DEALS, JANUARY 2021–APRIL 2024 275
14.9.3 EXPANSIONS 276
・ TABLE 355 LIQUID BIOPSY MARKET: EXPANSIONS, JANUARY 2021–APRIL 2024 276

15 COMPANY PROFILES 277

15.1 KEY PLAYERS 277
(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW, KEY STRATEGIES, STRATEGIC CHOICES MADE, AND WEAKNESSES AND COMPETITIVE THREATS)*
15.1.1 NATERA, INC. 277
・ TABLE 356 NATERA, INC.: COMPANY OVERVIEW 277
・ FIGURE 44 NATERA, INC.: COMPANY SNAPSHOT (2023) 278
・ TABLE 357 NATERA, INC.: PRODUCTS OFFERED 278
・ TABLE 358 NATERA, INC.: DEALS 279
15.1.2 QIAGEN 280
・ TABLE 359 QIAGEN: COMPANY OVERVIEW 280
・ FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2023) 281
・ TABLE 360 QIAGEN: PRODUCTS OFFERED 281
・ TABLE 361 QIAGEN: PRODUCT LAUNCHES & APPROVALS 282
・ TABLE 362 QIAGEN: DEALS 283
・ TABLE 363 QIAGEN: EXPANSIONS 284
15.1.3 MYRIAD GENETICS, INC. 285
・ TABLE 364 MYRIAD GENETICS, INC.: COMPANY OVERVIEW 285
・ FIGURE 46 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2023) 285
・ TABLE 365 MYRIAD GENETICS, INC.: PRODUCTS OFFERED 286
・ TABLE 366 MYRIAD GENETICS, INC.: PRODUCT LAUNCHES 286
・ TABLE 367 MYRIAD GENETICS, INC.: DEALS 286
15.1.4 ILLUMINA, INC. 289
・ TABLE 368 ILLUMINA, INC.: COMPANY OVERVIEW 289
・ FIGURE 47 ILLUMINA, INC.: COMPANY SNAPSHOT (2023) 290
・ TABLE 369 ILLUMINA, INC.: PRODUCTS OFFERED 290
・ TABLE 370 ILLUMINA, INC.: PRODUCT LAUNCHES 291
・ TABLE 371 ILLUMINA, INC.: DEALS 291
・ TABLE 372 ILLUMINA, INC.: EXPANSIONS 292
15.1.5 F. HOFFMANN-LA ROCHE LTD. 294
・ TABLE 373 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 294
・ FIGURE 48 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023) 295
・ TABLE 374 F. HOFFMAN-LA ROCHE LTD.: PRODUCTS OFFERED 295
・ TABLE 375 F. HOFFMAN-LA ROCHE LTD.: PRODUCT LAUNCHES 296
15.1.6 THERMO FISHER SCIENTIFIC INC. 297
・ TABLE 376 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 297
・ FIGURE 49 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 298
・ TABLE 377 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 298
・ TABLE 378 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES 299
・ TABLE 379 THERMO FISHER SCIENTIFIC INC.: DEALS 299
・ TABLE 380 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS 300
15.1.7 GUARDANT HEALTH 301
・ TABLE 381 GUARDANT HEALTH: COMPANY OVERVIEW 301
・ FIGURE 50 GUARDANT HEALTH: COMPANY SNAPSHOT (2023) 302
・ TABLE 382 GUARDANT HEALTH: PRODUCTS OFFERED 302
・ TABLE 383 GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS 303
・ TABLE 384 GUARDANT HEALTH: DEALS 304
15.1.8 BIO-RAD LABORATORIES, INC. 306
・ TABLE 385 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 306
・ FIGURE 51 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023) 307
・ TABLE 386 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 307
・ TABLE 387 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES 308
・ TABLE 388 BIO-RAD LABORATORIES, INC.: DEALS 308
15.1.9 EXACT SCIENCES CORPORATION 309
・ TABLE 389 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW 309
・ FIGURE 52 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2023) 310
・ TABLE 390 EXACT SCIENCES CORPORATION: PRODUCTS OFFERED 310
・ TABLE 391 EXACT SCIENCES CORPORATION: DEALS 311
15.1.10 SYSMEX CORPORATION 313
・ TABLE 392 SYSMEX CORPORATION: COMPANY OVERVIEW 313
・ FIGURE 53 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022) 313
・ TABLE 393 SYSMEX CORPORATION: PRODUCTS OFFERED 314
・ TABLE 394 SYSMEX CORPORATION: DEALS 314
・ TABLE 395 SYSMEX CORPORATION: EXPANSIONS 315
15.1.11 BIOCEPT, INC. 316
・ TABLE 396 BIOCEPT, INC.: COMPANY OVERVIEW 316
・ FIGURE 54 BIOCEPT, INC.: COMPANY SNAPSHOT (2022) 316
・ TABLE 397 BIOCEPT, INC.: PRODUCTS OFFERED 317
・ TABLE 398 BIOCEPT, INC.: PRODUCT LAUNCHES 317
・ TABLE 399 BIOCEPT, INC.: DEALS 317
15.1.12 MDXHEALTH 319
・ TABLE 400 MDXHEALTH: COMPANY OVERVIEW 319
・ FIGURE 55 MDXHEALTH: COMPANY SNAPSHOT (2022) 319
・ TABLE 401 MDXHEALTH: PRODUCTS OFFERED 320
・ TABLE 402 MDXHEALTH: DEALS 320
15.1.13 PERSONALIS, INC. 321
・ TABLE 403 PERSONALIS, INC.: COMPANY OVERVIEW 321
・ FIGURE 56 PERSONALIS, INC.: COMPANY SNAPSHOT (2023) 321
・ TABLE 404 PERSONALIS, INC.: PRODUCTS OFFERED 322
・ TABLE 405 PERSONALIS, INC.: PRODUCT LAUNCHES 322
・ TABLE 406 PERSONALIS, INC.: DEALS 323
15.2 OTHER PLAYERS 325
15.2.1 NEOGENOMICS LABORATORIES 325
15.2.2 EPIGENOMICS AG 325
15.2.3 ANGLE PLC 326
15.2.4 MENARINI-SILICON BIOSYSTEMS 327
15.2.5 LUNGLIFE AI, INC. 328
15.2.6 VORTEX BIOSCIENCES 328
15.2.7 BIO-TECHNE 329
15.2.8 MESA LABS, INC. 330
15.2.9 LABORATORY CORPORATION OF AMERICA HOLDINGS 331
15.2.10 MEDGENOME 332
15.2.11 STRAND 333
15.2.12 FREENOME HOLDINGS, INC. 333
15.2.13 LUCENCE HEALTH INC. 334
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW, KEY STRATEGIES, STRATEGIC CHOICES MADE, AND WEAKNESSES AND COMPETITIVE THREATS MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.

16 APPENDIX 335

16.1 DISCUSSION GUIDE 335
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 340
16.3 CUSTOMIZATION OPTIONS 342
16.4 RELATED REPORTS 342
16.5 AUTHOR DETAILS 343

△ 一番上に戻る